Formulation development of albumin based theragnostic nanoparticles as a potential delivery system for tumor targeting

Journal of Drug Targeting

Volumn 21, Issue 1, 2013, Pages 77-86

  Kolluru, Lakshmi Prasanna ^a   Rizvi, Syed A A ^b   D'Souza, Marissa ^c   D'Souza, Martin J ^a  

^a MERCER UNIVERSITY   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

^c North View High School   (United States)

Author keywords

Albumin nanoparticles; Design of experiments; Factorial design; Nanoprecipitation; Non invasive imaging; Tumor targeting

Indexed keywords

ALBUMIN; DYE; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER LOCALIZATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; DRUG TARGETING; FEMALE; FREEZE DRYING; IN VIVO STUDY; MALE; MOUSE; NANOPRECIPITATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; ZETA POTENTIAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMICAL PRECIPITATION; COLORING AGENTS; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FEMALE; FREEZE DRYING; INDOCYANINE GREEN; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; SERUM ALBUMIN, BOVINE;

EID: 84872022208     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.729214     Document Type: Article

References (42)

1. Anhorn MG, Mahler HC, Langer K. (2008a). Freeze drying of human serum albumin (HSA) nanoparticles with diferent excipients. Int J Pharm, 363, 162-169.
2. Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H. (2008b). Specifc targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modifed human serum albumin nanoparticles. Bioconjug Chem, 19, 2321-2331.
3. Bejugam NK, Uddin AN, Gayakwad SG, D'Souza MJ. (2008). Formulation and evaluation of albumin microspheres and its enteric coating using a spray-dryer. J Microencapsul, 25, 577-583.
4. Bhojani MS, Van Dort M, Rehemtulla A, Ross BD. (2010). Targeted imaging and therapy of brain cancer using theranostic nanoparticles. Mol Pharm, 7, 1921-1929.
5. Bilati U, Allémann E, Doelker E. (2005). Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci, 24, 67-75.
6. Chablani L, Tawde SA, D'Souza MJ. (2012). Spray-dried microparticles: a potential vehicle for oral delivery of vaccines. J Microencapsul, 29, 388-397.
7. Chen D, Zhang Z, Cao J, Zhang D, Jia B. (2010). [Efect of glucosamine hydrochloride capsules on articular cartilage of rabbit knee joint in osteoarthritis]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 24, 287-291.
8. Chorny M, Fishbein I, Danenberg HD, Golomb G. (2002). Lipophilic drug loaded nanospheres prepared by nanoprecipitation: efect of formulation variables on size, drug recovery and release kinetics. J Control Release, 83, 389-400.
9. Cortes J, Saura C. (2010). Nanoparticle albumin-bound (nab™)-paclitaxel: improving efcacy and tolerability by targeted drug delivery in metastatic breast cancer. EJC Supplements, 8, 1-10.
10. Desai ND. (2007). Nanoparticle albumin bound (nab) technology: targeting tumors through the endothelial gp60 receptor and SPARC. Nanomedicine, 337-346.
11. El-Leithy ES, Shaker DS, Ghorab MK, Abdel-Rashid RS. (2010). Optimization and characterization of diclofenac sodium microspheres prepared by a modifed coacervation method. Drug Discov Ter, 4, 208-216.
12. Gayakwad SG, Bejugam NK, Akhavein N, Uddin NA, Oettinger CE, D'Souza MJ. (2009). Formulation and in vitro characterization of spray-dried antisense oligonucleotide to NF-kappaB encapsulated albumin microspheres. J Microencapsul, 26, 692-700.
13. Greish K, Iyer A, Fang J, Kawasuji M, Maeda H. (2006). Enhanced Permeability and Retention (EPR) Efect and Tumor-Selective Delivery of Anticancer Drugs. Delivery of protein and peptide drugs in cancer. 37-52.
14. Greish K. (2010). Enhanced permeability and retention (EPR) efect for anticancer nanomedicine drug targeting. In: Grobmeyer SR, Moudgil BM. Cancer nanotechnology: methods and protocols. New York, NY: Humana Press.
15. Hadjiioannou TP, Christian GD, Koupparis MA. (1993). Quantitative calculations in pharmaceutical practice and research. New York, NY: VCH Publishers Inc.
16. Higuchi T. (1963). Mechanism of sustained-action medication. theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci, 52, 1145-1149.
17. Hixson AW, Crowell JH. (1931). Dependence of reaction velocity upon surface and agitation: I-theoretical consideration. Ind Eng Chem, 23, 923-931.
18. Hornig S, Bunjes H, Heinze T. (2009). Preparation and characterization of nanoparticles based on dextran-drug conjugates. J Colloid Interface Sci, 338, 56-62.
19. Janib SM, Moses AS, MacKay JA. (2010). Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev, 62, 1052-1063.
20. Jones AK, Bejugam NK, Nettey H, Addo R, D'Souza MJ. (2011). Spray-dried doxorubicin-albumin microparticulate systems for treatment of multidrug resistant melanomas. J Drug Target, 19, 427-433.
21. Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MN. (2009). Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res, 26, 492-501.
22. Kheirolomoom A, Mahakian LM, Lai CY, Lindfors HA, Seo JW, Paoli EE, Watson KD, Haynam EM, Ingham ES, Xing L, Cheng RH, Borowsky AD, Cardif RD, Ferrara KW. (2010). Copper-doxorubicin as a nanoparticle cargo retains efcacy with minimal toxicity. Mol Pharm, 7, 1948-1958.
23. Korsemeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. (1983). Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm, 15, 25-35.
24. Krishna R, Mayer LD. (2000). Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in infuencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci, 11, 265-283.
25. Liu Y, Miyoshi H, Nakamura M. (2007). Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer, 120, 2527-2537.
26. Masotti A, Vicennati P, Boschi F, Calderan L, Sbarbati A, Ortaggi G. (2008). A novel near-infrared indocyanine dye-polyethylenimine conjugate allows DNA delivery imaging in vivo. Bioconjug Chem, 19, 983-987.
27. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. (2009). Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine, 4, 99-105.
28. Mohan P, Rapoport N. (2010). Doxorubicin as a molecular nanotheranostic agent: efect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafcking. Mol Pharm, 7, 1959-1973.
29. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. (2007). Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol, 2, 751-760.
30. Sahoo SK, Labhasetwar V. (2003). Nanotech approaches to drug delivery and imaging. Drug Discov Today, 8, 1112-1120.
31. Saxena V, Sadoqi M, Shao J. (2006). Polymeric nanoparticulate delivery system for Indocyanine green: biodistribution in healthy mice. Int J Pharm, 308, 200-204.
32. Shastri PN, Ubale RV, D'Souza MJ. (2012). Implementation of mixture design for formulation of albumin containing enteric-coated spray-dried microparticles. Drug Dev Ind Pharm. DOI: 10.3109/03639045.2012.664148
33. Shen Z, Wei W, Zhao Y, Ma G, Dobashi T, Maki Y, Su Z, Wan J. (2008). Termosensitive polymer-conjugated albumin nanospheres as thermal targeting anti-cancer drug carrier. Eur J Pharm Sci, 35, 271-282.
34. Shen Z, Li Y, Kohama K, Oneill B, Bi J. (2011). Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres. Pharmacol Res, 63, 51-58.
35. Sun C, Lee JS, Zhang M. (2008). Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev, 60, 1252-1265.
36. Ulbrich K, Michaelis M, Rothweiler F, Knobloch T, Sithisarn P, Cinatl J, Kreuter J. (2011). Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells. Int J Pharm, 406, 128-134.
37. Veiseh O, Gunn JW, Zhang M. (2010). Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev, 62, 284-304.
38. Vijayaraghavalu S, Raghavan D, Labhasetwar V. (2007). Nanoparticles for delivery of chemotherapeutic agents to tumors. Curr Opin Investig Drugs, 8, 477-484.
39. Vogel SM, Minshall RD, Pilipovic M, Tiruppathi C, Malik AB. (2001). Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am J Physiol Lung Cell Mol Physiol, 281, L1512-L1522.
40. Wang G, Siggers K, Zhang S, Jiang H, Xu Z, Zernicke RF, Matyas J, Uludag H. (2008). Preparation of BMP-2 containing bovine serum albumin (BSA) nanoparticles stabilized by polymer coating. Pharm Res, 25, 2896-2909.
41. Wang M, Tanou M. (2010). Targeting nanoparticles to cancer. Pharmacol Res, 62, 90-99.
42. Weissleder R. (2001). A clearer vision for in vivo imaging. Nat Biotechnol, 19, 316-317.